OncoMatch/Clinical Trials/NCT06902246
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Is NCT06902246 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Regorafenib for unresectable hepatocellular carcinoma.
Treatment: Regorafenib — The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: radioembolization
Prior radioembolization
Lab requirements
Blood counts
Platelet count > 100,000/mm3; hemoglobin (Hb) 9 g/dL; ANC 1,500/mm3
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Child-Pugh A-B7; Serum bilirubin < 1.5 ULN; AST and ALT < 5 x ULN
Cardiac function
No active or clinically significant cardiac disease including: congestive heart failure (NYHA > Class II), active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, new-onset angina within 3 months, or myocardial infarction within 6 months
Child-Pugh A-B7. Serum bilirubin < 1.5 ULN; AST and ALT < 5 x ULN. Serum creatinine ≤ 1.5 x ULN. Platelet count > 100,000/mm3, hemoglobin (Hb) 9 g/dL, and absolute neutrophil count (ANC) 1,500/mm3. Active or clinically significant cardiac disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify